Navigation Links
FDA Panel Gives Blessing to New Weight-Loss Drug
Date:5/12/2012

THURSDAY, May 10 (HealthDay News) -- An advisory panel to the U.S. Food and Drug Administration on Thursday recommended approval of the weight-loss medication lorcaserin, even though concerns remain about cardiovascular side effects.

If the agency were to give the nod to the drug, lorcaserin would become the first new weight-loss pill made available to Americans in a decade. The FDA is not bound to follow the advice of its expert panels, but it typically does.

The panel of experts voted 18 to 4, with one abstention, for approval, saying the drug's benefits "outweigh the potential risks when used long term" for people battling excess weight, the Associated Press reported.

Lorcaserin has not always received such a favorable reception. According to the AP, in 2010 scientists voiced concern that the drug might come with health risks, citing tumors that had developed in animal testing involving the drug.

However, Arena Pharmaceuticals, the San Francisco-based company that makes lorcaserin, has since submitted additional data in hopes the FDA might look more favorably on the drug.

According to a review of the available research posted by FDA staff online on Tuesday, that new data suggests that lorcaserin carries only a "negligible risk" of cancer in humans, the AP said. But concerns over the potential for cardiovascular risks -- hypertension in people with diabetes, for example, or injury to heart valves -- remain.

According to the AP, lorcaserin is one of three experimental weight-loss drugs that the FDA is taking a second look at after first saying no to the medications in 2010 or early 2011 because of concerns about significant side effects.

In February, another new weight-loss drug, Qnexa, was endorsed by an FDA advisory panel. The agency is expected to make a final decision on Qnexa in July.

More information

Find out more about healthy weight loss at the U.S. Centers for Disease Control and Prevention.

-- E.J. Mundell

SOURCE: Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Panel Rejects Ovarian Cancer Screening
2. Panel of serum biomarkers may reduce number of lung biopsies needed
3. FDA Panel Cites Clot Risk From Contraceptive Patch
4. Panel endorses active monitoring and delay of treatment for low-risk prostate cancer
5. Expert Panel Pinpoints Environmental Culprits in Breast Cancer
6. FDA Panels to Weigh Safety of Newer Forms of the Pill
7. Panel of melanoma mutations opens door to new treatment possibilities
8. Many on Medical Guideline Panels Have Conflicts of Interest: Study
9. Panels Rejection of PSA Test Spurs Mixed Reaction From Experts
10. Osteoporosis Drugs Safety Subject of FDA Panel
11. U.S. Panel Recommends Free Coverage of Birth Control
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Gives Blessing to New Weight-Loss Drug 
(Date:4/28/2017)... ... April 28, 2017 , ... ... Patel M.D. has joined the revolutionary endoscopic practice under Dr. Datta. Patel is ... Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), ... labor and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding ... the hospital and decide to donate. , “Women’s Hospital at Renaissance has been ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
(Date:4/28/2017)... ... 2017 , ... Bill Howe started his sewer and drain company in 1980 ... joined the team, the Bill Howe brand was born and they began cultivating their ... back to the San Diego community in which they worked, lived and were raising ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: